CR10211A - Compuestos de tiazol y métodos de uso - Google Patents

Compuestos de tiazol y métodos de uso

Info

Publication number
CR10211A
CR10211A CR10211A CR10211A CR10211A CR 10211 A CR10211 A CR 10211A CR 10211 A CR10211 A CR 10211A CR 10211 A CR10211 A CR 10211A CR 10211 A CR10211 A CR 10211A
Authority
CR
Costa Rica
Prior art keywords
compounds
tiazol
methods
compositions
formula
Prior art date
Application number
CR10211A
Other languages
English (en)
Spanish (es)
Inventor
Qingping Zeng
John G Allen
Matthew P Bourbeau
Celia Dominguez
Christopher H Fotsch
Nianhe Han
Fang-Tsao Hong
Xin Huang
Matthew R Lee
Aiwen Li
Qingyian Liu
James T Rider
Seifu Tadesse
Andrew S Tasker
Vellarkad N Viswanadhan
Xianghong Wang
Kurt E Weiler
George E Wohlhieter
Guomin Yao
Chester Chenguang Yuan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR10211A publication Critical patent/CR10211A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
CR10211A 2006-01-18 2008-08-18 Compuestos de tiazol y métodos de uso CR10211A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18

Publications (1)

Publication Number Publication Date
CR10211A true CR10211A (es) 2008-10-03

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10211A CR10211A (es) 2006-01-18 2008-08-18 Compuestos de tiazol y métodos de uso

Country Status (21)

Country Link
US (2) US7514566B2 (US08084479-20111227-C00055.png)
EP (1) EP1981884B1 (US08084479-20111227-C00055.png)
JP (1) JP5199885B2 (US08084479-20111227-C00055.png)
KR (1) KR20080091369A (US08084479-20111227-C00055.png)
CN (1) CN101421265A (US08084479-20111227-C00055.png)
AR (1) AR059064A1 (US08084479-20111227-C00055.png)
AU (1) AU2007207743B2 (US08084479-20111227-C00055.png)
BR (1) BRPI0706621A2 (US08084479-20111227-C00055.png)
CA (1) CA2636077C (US08084479-20111227-C00055.png)
CR (1) CR10211A (US08084479-20111227-C00055.png)
EA (1) EA200801716A1 (US08084479-20111227-C00055.png)
ES (1) ES2389062T3 (US08084479-20111227-C00055.png)
IL (1) IL192751A0 (US08084479-20111227-C00055.png)
MY (1) MY149143A (US08084479-20111227-C00055.png)
NO (1) NO20083572L (US08084479-20111227-C00055.png)
PE (1) PE20071114A1 (US08084479-20111227-C00055.png)
TW (1) TW200738657A (US08084479-20111227-C00055.png)
UA (1) UA91895C2 (US08084479-20111227-C00055.png)
UY (1) UY30098A1 (US08084479-20111227-C00055.png)
WO (1) WO2007084391A2 (US08084479-20111227-C00055.png)
ZA (1) ZA200806386B (US08084479-20111227-C00055.png)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354944B2 (en) 2004-10-18 2008-04-08 Amgen Inc. Thiadiazole compounds and methods of use
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
RU2009134059A (ru) * 2007-02-13 2011-03-20 Шеринг Корпорейшн (US) Функционально селективные агонисты альфа2с адренорецептора
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
AU2008276521B2 (en) * 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP2011525929A (ja) * 2008-06-26 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害剤
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
KR20110042374A (ko) * 2008-08-18 2011-04-26 예일 유니버시티 Ｍｉｆ 조정인자
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
PT3135672T (pt) * 2008-10-10 2020-04-02 Vm Discovery Inc Composições e métodos para o tratamento distúrbios de utilização de álcool, dor e outras doenças
MX2011006509A (es) * 2008-12-19 2011-10-19 Genentech Inc Compuestos heterociclicos y métodos de uso.
US20110263647A1 (en) * 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
WO2010151689A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011044415A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
PL2485593T3 (pl) * 2009-10-08 2015-06-30 Novartis Ag Kombinacja
EP2488184A4 (en) * 2009-10-12 2013-04-24 Glaxosmithkline Llc COMBINATION
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
LT2496567T (lt) 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
CN102884068A (zh) * 2010-03-15 2013-01-16 国立大学法人广岛大学 噻吩并吡啶衍生物及其制备方法、以及使用该衍生物的有机半导体器件
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 （アリール）ジフルオロ酢酸エステル誘導体及びその製造方法
EP2558459B1 (en) * 2010-04-16 2014-01-22 Abbvie Inc. Phthalazin-(2h)-one inhibitors of kinases
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20130102605A1 (en) * 2010-04-23 2013-04-25 Peng Liang Inhibitors of akt activity
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103304468A (zh) * 2012-03-13 2013-09-18 华东师范大学 一种氧化吲哚的一锅法串联合成方法
WO2013146754A1 (ja) * 2012-03-27 2013-10-03 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
KR102216606B1 (ko) 2012-07-04 2021-02-17 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
AU2014219075C1 (en) 2013-02-19 2018-09-06 Amgen Inc. Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP6378308B2 (ja) * 2013-03-13 2018-08-22 ボストン バイオメディカル， インコーポレイテッド がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
LT3068393T (lt) 2013-11-11 2022-08-10 Amgen Inc. Kombinuota terapija, įskaitant mdm2 inhibitorių ir vieną arba daugiau papildomų farmaciškai aktyvių agentų, skirta vėžiui gydyti
US9884868B2 (en) * 2015-03-02 2018-02-06 Rigel Pharmaceuticals, Inc. TGF-beta inhibitors
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
KR20180117693A (ko) * 2016-03-10 2018-10-29 아스트라제네카 아베 포스파티딜이노시톨 3-키나제 감마의 신규 억제제
WO2018183964A1 (en) 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
AU2020280024A1 (en) 2019-05-21 2021-12-09 Amgen Inc. Solid state forms
MX2022001302A (es) * 2019-08-02 2022-03-02 Amgen Inc Inhibidores de kif18a.
EP4045047A1 (en) 2019-10-15 2022-08-24 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
CN111603466B (zh) * 2020-06-29 2022-07-22 江南大学 一种乙酮类化合物在制备治疗肿瘤药物中的应用
CN114014787B (zh) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) * 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (US08084479-20111227-C00055.png) 1973-11-08 1977-10-07
US4086239A (en) * 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US4451471A (en) * 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (fr) * 1981-08-17 1983-02-18 Rhone Poulenc Sante Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent
DE3630732A1 (de) * 1986-09-10 1988-03-17 Bayer Ag 2-cyano-2-alkoximino-acetamide
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (ja) 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
FR2636628B1 (fr) * 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
US5302608A (en) * 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) * 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
DE69526958T2 (de) * 1994-11-29 2003-01-16 Hisamitsu Pharmaceutical Co Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
DE69923681T2 (de) 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2000045635A1 (en) 1999-02-08 2000-08-10 Lion Bioscience Ag Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd ｐ３８ＭＡＰキナーゼ阻害剤
CA2381215A1 (en) * 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
AU2001249670A1 (en) * 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
US7074934B2 (en) * 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP4689801B2 (ja) 2000-08-09 2011-05-25 ケミプロ化成株式会社 アミノチアゾール誘導体の製造方法
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
CA2450400A1 (en) * 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
EP1760082A1 (en) * 2001-09-28 2007-03-07 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
JP2005510508A (ja) * 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
JP2005526720A (ja) 2002-02-13 2005-09-08 ファーマジーン ラボラトリーズ リミテッド ５−ｈｔ２ｂ受容体アンタゴニスト
BR0308108A (pt) * 2002-02-28 2004-12-07 Hoffmann La Roche Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
AR038703A1 (es) * 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AU2003290507A1 (en) * 2002-05-10 2004-04-08 Cytokinetics, Inc. Compounds, compositions and methods
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
OA12937A (en) * 2002-10-09 2006-10-13 Pfizer Prod Inc Thiazole compounds for the treatment of neurodegenerative disorders.
NZ540161A (en) * 2002-10-30 2008-03-28 Vertex Pharma Compositions useful as inhibitors of rock and other protein kinases
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
ATE536353T1 (de) * 2003-08-20 2011-12-15 Vertex Pharma 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
ZA200602755B (en) * 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
PL1709019T3 (pl) 2004-01-12 2007-10-31 Merck Serono Sa Tiazolowe pochodne i ich zastosowanie
EP1709041A1 (fr) * 2004-01-16 2006-10-11 Sanofi-Aventis Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
PT1709018E (pt) * 2004-01-16 2011-10-24 Sanofi Sa Derivados de acilaminotiazole e sua aplicação como inibidores
EP1720855A4 (en) * 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
CA2560580C (en) 2004-03-23 2008-12-23 Pfizer Products Inc. Imidazole compounds for inhibition of a.beta.-peptide production and for modulation of the notch signaling pathway
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
WO2005116052A2 (en) * 2004-04-27 2005-12-08 Research Development Foundation ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
AU2005245962A1 (en) * 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
KR20070049655A (ko) 2004-08-13 2007-05-11 제넨테크, 인크. Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
US7354944B2 (en) * 2004-10-18 2008-04-08 Amgen Inc. Thiadiazole compounds and methods of use
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1854793A4 (en) * 2005-02-28 2011-01-26 Japan Tobacco Inc NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
AU2006261327B2 (en) * 2005-06-17 2012-07-05 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
US7871982B2 (en) 2005-12-09 2011-01-18 Meiji Seika Kaisha, Ltd. Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient
WO2007070600A2 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
AU2007207052B2 (en) 2006-01-18 2012-07-12 F. Hoffmann-La Roche Ag CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors
AU2007207706A1 (en) 2006-01-18 2007-07-26 Merck Sharp & Dohme Corp. Cannibinoid receptor modulators
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
JP5199885B2 (ja) 2013-05-15
NO20083572L (no) 2008-10-17
WO2007084391A3 (en) 2008-03-20
BRPI0706621A2 (pt) 2011-04-05
US20070173506A1 (en) 2007-07-26
MY149143A (en) 2013-07-15
UA91895C2 (en) 2010-09-10
WO2007084391A2 (en) 2007-07-26
UY30098A1 (es) 2007-10-31
ES2389062T3 (es) 2012-10-22
CA2636077A1 (en) 2007-07-26
JP2009525960A (ja) 2009-07-16
US20090270445A1 (en) 2009-10-29
EP1981884A2 (en) 2008-10-22
CA2636077C (en) 2012-01-03
ZA200806386B (en) 2009-11-25
EA200801716A1 (ru) 2009-04-28
US7514566B2 (en) 2009-04-07
AU2007207743B2 (en) 2010-07-08
AR059064A1 (es) 2008-03-12
US8084479B2 (en) 2011-12-27
CN101421265A (zh) 2009-04-29
EP1981884B1 (en) 2012-06-13
KR20080091369A (ko) 2008-10-10
AU2007207743A1 (en) 2007-07-26
PE20071114A1 (es) 2008-01-10
TW200738657A (en) 2007-10-16
IL192751A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
CR10211A (es) Compuestos de tiazol y métodos de uso
WO2009011880A3 (en) Heterocyclic modulators of pkb
WO2009011871A3 (en) Thiadiazole modulators of pkb
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
NI200700296A (es) Imidazoquinolinas como inhibidores de cinasa de lipido
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
ECSP066833A (es) Compuestos heterocíclicos anticitocina
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
BR112012012815A8 (pt) composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
ATE530524T1 (de) Substituierte sulfonamid-derivate
CR20110103A (es) Heteroarilos sustituidos
NI200800253A (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
ECSP12011748A (es) Derivados de 3,5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos
UY28792A1 (es) Compuestos heterocíclicos anticitocina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)